Olverembatinib Plus Venetoclax and Dexamethasone for Treatment-naïve Ph+ Acute Lymphoblastic Leukemia
Status:
Recruiting
Trial end date:
2026-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore the efficacy and safety of the OVD chemotherapy-free
regimen (Olverembatinib, venetoclax and dexamethasone) in patients with newly-diagnosed
Ph+ALL.